Anabolic effects of bisphosphonates on peri-implant bone stock

Biomaterials

Volumn 28, Issue 24, 2007, Pages 3549-3559

  von Knoch, Fabian ^a   Eckhardt, Christina ^a   Alabre, Claude I ^a   Schneider, Erich ^a   Rubash, Harry E ^a   Shanbhag, Arun S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alendronate; Bisphosphonates; Total joint replacements; UHMWPE; Wear debris; Zoledronate

Indexed keywords

DURABILITY; HISTOLOGY; IMPLANTS (SURGICAL); PHOSPHORUS COMPOUNDS; POLYETHYLENES; RADIOGRAPHY; THICKNESS MEASUREMENT; TITANIUM ALLOYS;

ALENDRONATES; BISPHOSPHONATES; TOTAL JOINT REPLACEMENTS; WEAR DEBRIS; ZOLEDRONATES;

BONE;

ALENDRONIC ACID; ALUMINUM; TITANIUM; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE; VANADIUM; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; CORTICAL BONE; FEMUR; IMPLANT; JOINT PROSTHESIS; JOINT RADIOGRAPHY; MOLECULAR WEIGHT; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RABBIT; THICKNESS;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; DIPHOSPHONATES; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 34249285919     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.04.024     Document Type: Article

References (50)

1. Jacobs J.J., Roebuck K.A., Archibeck M., Hallab N.J., and Glant T.T. Osteolysis: basic science. Clin Orthop 393 (2001) 71-77
2. Sinha R.K., Shanbhag A.S., Maloney W.J., Hasselman C.T., and Rubash H.E. Osteolysis: cause and effect. Instr Course Lect 47 (1998) 307-320
3. Goldring S.R., Schiller A.L., Roelke M., Rourke C.M., O'Neil D.A., and Harris W.H. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Jt Surg Am 65 5 (1983) 575-584
4. Willert H.G. Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res 11 2 (1977) 157-164
5. Shanbhag A.S., Jacobs J.J., Black J., Galante J.O., and Glant T.T. Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty 10 4 (1995) 498-506
6. Shanbhag A.S., Sethi M., and Rubash H.E. Biologic response to wear debris: cellular interactions causing osteolysis. In: Callaghan J.J., Rosenberg A.G., and Rubash H.E. (Eds). The adult hip (2006), Lippincott-Raven Publishers, Philadelphia, PA
7. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 5484 (2000) 1508-1514
8. Shanbhag A.S., Hasselman C.T., and Rubash H.E. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 344 (1997) 33-43
9. Fischer K.J., Vikoren T.H., Ney S., Kovach C., Hasselman C., Agrawal M., et al. Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs. J Biomed Mater Res B Appl Biomater 76 1 (2006) 143-148
10. Im G.I., Qureshi S.A., Kenney J., Rubash H.E., and Shanbhag A.S. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25 18 (2004) 4105-4115
11. Shanbhag A.S. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 14 4 (2006) 215-225
12. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 12 (2004) 1189-1199
13. Lehmann H.J., Mouritzen U., Christgau S., Cloos P.A., and Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61 6 (2002) 530-533
14. Maksymowych W.P. Bisphosphonates for arthritis-a confusing rationale. J Rheumatol 30 3 (2003) 430-434
15. Venesmaa P.K., Kroger H.P., Miettinen H.J., Jurvelin J.S., Suomalainen O.T., and Alhav E.M. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 16 11 (2001) 2126-2131
16. von Knoch M., Wedemeyer C., Pingsmann A., von Knoch F., Hilken G., Sprecher C., et al. The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials 26 14 (2005) 1803-1808
17. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 4 (1998) 581-589
18. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286 5446 (1999) 1946-1949
19. von Knoch F., Wedemeyer C., Heckelei A., Saxler G., Hilken G., Brankamp J., et al. Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis. Biomaterials 26 29 (2005) 5783-5789
20. von Knoch F., Jaquiery C., Kowalsky M., Schaeren S., Alabre C., Martin I., et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26 34 (2005) 6941-6949
21. Fromigue O., and Body J.J. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25 6 (2002) 539-546
22. Giuliani N., Pedrazzoni M., Negri G., Passeri G., Impicciatore M., and Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22 5 (1998) 455-461
23. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., and Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104 10 (1999) 1363-1374
24. Cho D.R., Shanbhag A.S., Hong C.Y., Baran G.R., and Goldring S.R. The role of adsorbed endotoxin in particle-induced stimulation of cytokine release. J Orthop Res 20 4 (2002) 704-713
25. Shanbhag A.S., Hasselman C.T., and Rubash H.E. Technique for generating submicrometer ultra high molecular weight polyethylene particles. J Orthop Res 14 6 (1996) 1000-1004
26. Shanbhag A.S., Jacobs J.J., Glant T.T., Gilbert J.L., Black J., and Galante J.O. Composition and morphology of wear debris in failed uncemented total hip replacement. J Bone Jt Surg Br 76 1 (1994) 60-67
27. Feighan J.E., Goldberg V.M., Davy D., Parr J.A., and Stevenson S. The influence of surface-blasting on the incorporation of titanium-alloy implants in a rabbit intramedullary model. J Bone Jt Surg 77-A (1995) 1380-1395
28. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 9 (2002) 653-661
29. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 6 (1987) 595-610
30. Mitlak B.H., Schoenfeld D., and Neer R.M. Accuracy, precision, and utility of spine and whole-skeleton mineral measurements by DXA in rats. J Bone Miner Res 9 1 (1994) 119-126
31. Millett P.J., Allen M.J., and Bostrom M.P. Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Jt Surg Am 84-A 2 (2002) 236-249
32. Rauch F., Travers R., Plotkin H., and Glorieux F.H. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110 9 (2002) 1293-1299
33. Wang X., Shanbhag A.S., Rubash H.E., and Agrawal C.M. Short-term effects of bisphosphonates on the biomechanical properties of canine bone. J Biomed Mater Res 44 4 (1999) 456-460
34. Shanbhag A.S., May D., Cha C., Hasselman C.T., and Rubash H.E. Enhancing net bone formation in canine total hip components with bisphosphonates. Trans Orthop Res Soc 44 (1999) 255
35. Frenkel S.R., Jaffe W.L., Valle C.D., Jazrawi L., Maurer S., Baitner A., et al. The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model. J Biomed Mater Res 58 6 (2001) 645-650
36. Bobyn J.D., Hacking S.A., Krygier J.J., Harvey E.J., Little D.G., and Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Jt Surg Br 87 3 (2005) 416-420
37. Kajiwara H., Yamaza T., Yoshinari M., Goto T., Iyama S., Atsuta I., et al. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials 26 6 (2005) 581-587
38. Tanzer M., Karabasz D., Krygier J.J., Cohen R., and Bobyn J.D. The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res 441 (2005) 30-39
39. Peter B., Pioletti D.P., Laib S., Bujoli B., Pilet P., Janvier P., et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 36 1 (2005) 52-60
40. Wedemeyer C., von Knoch F., Pingsmann A., Hilken G., Sprecher C., Saxler G., et al. Stimulation of bone formation by zoledronic acid in particle-induced osteolysis. Biomaterials 26 17 (2005) 3719-3725
41. Vermes C., Chandrasekaran R., Jacobs J.J., Galante J.O., Roebuck K.A., and Glant T.T. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Jt Surg Am 83-A 2 (2001) 201-211
42. Wang M.L., Nesti L.J., Tuli R., Lazatin J., Danielson K.G., Sharkey P.F., et al. Titanium particles suppress expression of osteoblastic phenotype in human mesenchymal stem cells. J Orthop Res 20 6 (2002) 1175-1184
43. Vermes C., Chandrasekaran R., Dobai J.G., Jacobs J.J., Andersson G.B., An H., et al. The combination of pamidronate and calcitriol reverses particle- and TNF-alpha-induced altered functions of bone-marrow-derived stromal cells with osteoblastic phenotype. J Bone Jt Surg Br 86 5 (2004) 759-770
44. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 6 (1991) 2095-2105
45. Adami S., and Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 14 3 (1996) 158-170
46. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 5 (2000) 687-694
47. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19 6 (2004) 999-1005
48. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 6 (1997) 1475-1480
49. Day J.S., Ding M., Bednarz P., Van Der Linden J.C., Mashiba T., Hirano T., et al. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 22 3 (2004) 465-471
50. Wang C.J., Wang J.W., Weng L.H., Hsu C.C., Huang C.C., and Chen H.S. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Jt Surg Am 85-A 11 (2003) 2121-2126